Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Lauren Smith

Nurse Practitioner, Adult Health Saint Louis, MO Nurse Practitioner

NPI 1427675800 CMS profile 11206670

915 N Grand Blvd, Saint Louis, MO 63106

Open in the dashboard

General payments

$5,808

224 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Smith of Saint Louis, MO is reported in the CMS Open Payments database as having received $5,808 across 224 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,469 56
2024 General $2,020 73
2023 General $1,504 66
2022 General $815 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Smith
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Lauren Smith were reported at $1,469. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Lauren Smith Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $138 $43–$438 $132
2022 $815 $165 $54–$494 $149
2023 $1,504 $178 $61–$549 $160
2024 $2,020 $186 $62–$575 $164
2025 $1,469 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Seattle Genetics, Inc. $731 16 payments
  2. Janssen Biotech, Inc. $505 20 payments
  3. Merck Sharp & Dohme Corporation $498 22 payments
  4. Daiichi Sankyo Inc. $446 8 payments
  5. Novartis Pharmaceuticals Corporation $382 20 payments
  6. Gilead Sciences, Inc. $349 4 payments
  7. Pfizer Inc. $304 16 payments
  8. Celgene Corporation $257 14 payments
  9. AstraZeneca Pharmaceuticals LP $212 10 payments
  10. Abiomed $188 4 payments
  11. Other $1,936 90 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,956 214 payments
  2. Education $852 10 payments
Products named General payments · program years 2022–2025
  1. KEYTRUDA $498 22 payments
  2. ENHERTU $446 8 payments
  3. Trodelvy $335 3 payments
  4. TUKYSA $219 10 payments
  5. DARZALEX $201 9 payments
  6. Impella $188 4 payments
  7. RYBREVANT $181 5 payments
  8. Lenvima $169 7 payments
  9. LYNPARZA $150 7 payments
  10. LIBTAYO $147 6 payments
  11. Other $4,053 205 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

700

Median for Nurse Practitioner: 389

Drug cost

$17,702

Median for Nurse Practitioner: $21,885

Branded share of claims

14.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Hcl Generic 124 $9,921
Letrozole Generic 71 $1,846
Prochlorperazine Maleate Generic 123 $1,126
Raloxifene Hcl Generic 23 $975
Pantoprazole Sodium Generic 161 $922
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 58 $737
Loperamide Loperamide Hcl Brand 31 $650
Dexamethasone Generic 37 $642
Acyclovir Generic 18 $304
Famotidine Generic 28 $263

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$20,215

Medicare's payments for the services billed

Medicare patients

219

Average age 74

Services billed

348

139 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 65%
Arthritis 54%
Chronic kidney disease 37%
Ischemic heart disease 36%
Diabetes 34%
Depression 32%
Heart failure 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 46 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Trodelvy
  • Gilead Sciences, Inc. $238
$238 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $182
$182 — —
ENHERTU
  • Daiichi Sankyo Inc. $126
  • AstraZeneca Pharmaceuticals LP $46
$172 — —
Lenvima
  • Eisai Inc. $125
$125 — —
RYBREVANT
  • Janssen Biotech, Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 46 with Patron

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record